推荐产品
等级
pharmaceutical primary standard
API类
leflunomide
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
格式
neat
SMILES字符串
Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F
InChI
1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
InChI key
VHOGYURTWQBHIL-UHFFFAOYSA-N
基因信息
human ... DHODH(1723)
正在寻找类似产品? 访问 产品对比指南
一般描述
Leflunomide is a drug with cytotoxic properties. It is generally used as an immunosuppressive agent.
应用
Leflunomide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Danger
危险分类
Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
靶器官
Respiratory system
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
S Greene et al.
Biochemical pharmacology, 50(6), 861-867 (1995-09-07)
Leflunomide [HWA 486 or RS-34821, 5-methyl-N-(4-trifluoromethylphenyl)-4-isoxazole carboximide] is an immunosuppressive agent effective in the treatment of rheumatoid arthritis. In spite of its clinical potential, its mechanism of action has not been elucidated. Recent studies suggest that leflunomide may interfere with
Robert P Baughman et al.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 21(1), 43-48 (2004-05-07)
Leflunomide (Arava) is a cytotoxic drug which has been used as a single agent or in combination with methotrexate for the treatment of rheumatoid arthritis. It appears to have less toxicity than methotrexate. The use of leflunomide for sarcoidosis patients
Young H Jung et al.
Pediatric transplantation, 17(2), E50-E54 (2012-12-06)
The BK virus (BKV) can be reactivated with immunosuppressive treatment in renal allograft recipients, which can result in interstitial nephritis (BKV-associated nephropathy, BKVAN) and lead to renal allograft failure. Recently, leflunomide has been reported in some case series of BKVAN
Helen I Keen et al.
Expert opinion on drug safety, 12(4), 581-588 (2013-05-15)
Leflunomide is a prodrug which is rapidly converted following oral administration and absorption to an active metabolite with anti-proliferative effects (A77 1726/teriflunomide). Leflunomide was developed as an immunomodulatory agent and subsequently developed as a disease-modifying anti-rheumatic drug (DMARD) for the
Shymaa E Bilasy et al.
Pharmacological reports : PR, 67(1), 102-114 (2015-01-07)
Safety of the combination of leflunomide and methotrexate was examined in several studies with inconclusive results. The present study was designed to compare the efficacy and safety of the combination of leflunomide and methotrexate in adjuvant-induced arthritis (AIA) in rats
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门